Skip to main content
SpringerLink
Log in

Translating Efficacy into Effectiveness in Antiretroviral Therapy

Beyond the Pill Count

  • Current Opinion
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Durable and sustained suppression of HIV replication can be achieved as demonstrated in several recent clinical trials of antiretroviral (ARV) regimens. However, the efficacy demonstrated in the experimental setting does not always translate to effectiveness in the clinical setting. The frequency and number of medications (conventionally referred to as the pill count) contribute to regimen effectiveness. However, clinicians and HIV-infected patients recognise that there are several other characteristics of an ARV regimen that are equally important contributors to its effectiveness. Potency and durability, the potential for drug-drug interactions, and the occurrence of adverse events also contribute to the effectiveness and complexity of a drug regimen. A comprehensive consideration of factors associated with efficacy will optimise the translation to effectiveness for the individual infected with HIV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Tapper ML, Daar ES, Piliero PJ, et al. Strategies for initiating combination antiretroviral therapy. AIDS Patient Care STDS 2005; 19(4): 224–38

    Article  PubMed  Google Scholar 

  2. Sax PE, Gathe Jr JC. Beyond efficacy: the impact of combination antiretroviral therapy on quality of life. AIDS Patient Care STDS 2005; 19(9): 563–76

    Article  PubMed  Google Scholar 

  3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21–30

    PubMed  CAS  Google Scholar 

  4. Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2001; 15: 2379–84

    Article  PubMed  CAS  Google Scholar 

  5. Munoz A, Hoover DR. Use of cohort studies for evaluating AIDS therapies. In: Finkelstein DM, Schoenfeld DA, editors. AIDS clinical trials. New York: Wiley-Liss Inc., 1995: 423–46

    Google Scholar 

  6. Munoz A, Gange SJ, Jacobson LP. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS 2000; 14: 754–6

    Article  PubMed  CAS  Google Scholar 

  7. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20: 2051–64

    Article  PubMed  CAS  Google Scholar 

  8. Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142 [abstract no. ThLB0204]. 16th International AIDS Conference; 2006 Aug 13–18; Toronto (ON)

  9. Moore RD, Keruly JC, Gebo KA, et al. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndrome 2005; 39: 195–8

    Google Scholar 

  10. Lampe FC, Gatell JM, Staszewski S, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006; 166: 521–8

    Article  PubMed  CAS  Google Scholar 

  11. Gail MH. Use of observational data for evaluating AIDS therapies. In: Finkelstein DM, Schoenfeld DA, editors. AIDS clinical trials. New York: Wiley-Liss Inc., 1995: 403–22

    Google Scholar 

  12. Miller LG, Huffman HB, Weidmer BA, et al. Patient preferences regarding antiretroviral therapy. Int J STD AIDS 2002; 13: 593–601

    Article  PubMed  Google Scholar 

  13. Sherer Jr RD, Fath MJ, Da Silva BA, et al. The importance of potency and durability in HIV patient antiretroviral therapy preferences: a telephone survey. AIDS Patient Care STDS 2005; 19: 794–802

    Article  PubMed  Google Scholar 

  14. Winston A, Patel N, Back D, et al. Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response. J Acquir Immune Defic Syndrome 2006; 41: 675–6

    Article  Google Scholar 

  15. Motwani B, Khayr W. Pharmacoenhancement of protease inhibitors. Am J Ther 2006; 13: 57–63

    Article  PubMed  Google Scholar 

  16. Eron Jr J, Yeni P, Gathe Jr J, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006; 368: 476–82

    Article  PubMed  CAS  Google Scholar 

  17. Qazi NA, Morlese JF, Pozniak AL. Lopinavir/ritonavir (ABT-378/r). Expert Opin Pharmacother 2002; 3: 315–27

    Article  PubMed  CAS  Google Scholar 

  18. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039–46

    Article  PubMed  CAS  Google Scholar 

  19. Acosta EP, King JR. Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clin Infect Dis 2003; 36: 373–7

    Article  PubMed  CAS  Google Scholar 

  20. Mocroft A, Phillips AN, Soriano V, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21: 527–36

    Article  PubMed  CAS  Google Scholar 

  21. Murphy R, Da Silva BA, McMillan F, et al. Seven year follow-up of a lopinavir/ritonovir (LPV/r)-based regimen in antiretroviral (ARV)-naive subjects [poster no. PE7.9/3]. 10th European AIDS Conference; 2005 Nov 17–20; Dublin

  22. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4 Suppl. 1: 1–41

    Article  PubMed  Google Scholar 

  23. Ruane P. Simplified antiretroviral regimens to improve quality of life. Simplification of antiretroviral therapy: optimizing quality-of-life concerns, volume 1 [online]. Available from URL: http://www.medscape.com/viewarticle/524241 [Accessed 2006 Jun 15]

  24. O’Brien ME, Clark RA, Besch CL, et al. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34: 407–14

    Article  PubMed  Google Scholar 

  25. Schrader S, Chuck SK, Rahn LW, et al. Switching to lopinavir/ritonavir (LPV/r) tablets once daily (TAB-QD) from soft-gelatin capsule dosed BID/QD (SGC-BID/SGC-QD) led to significant improvements in tolerability, diarrhea, antidiarrheal medication use, and satisfaction [poster no. 83]. 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 2006 Sep 24–26; San Francisco (CA)

  26. Johnson MA, Gathe Jr JC, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006; 43: 153–60

    Article  PubMed  CAS  Google Scholar 

  27. Louie M, Markowitz M. Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective. Antiviral Res 2002; 55: 15–25

    Article  PubMed  CAS  Google Scholar 

  28. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004; 36: 808–16

    Article  PubMed  Google Scholar 

  29. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001; 2(1): 38–45

    Article  PubMed  CAS  Google Scholar 

  30. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000; 30 Suppl. 2: S96–116

    Article  PubMed  CAS  Google Scholar 

  31. Williams A, Friedland G. Adherence, compliance, and HAART. AIDS Clin Care 1997; 9: 51–54, 58

    PubMed  CAS  Google Scholar 

  32. Piscitelli SC, Penzak SR, Flexner C. Practical therapeutics. In: Wormser GP, editor. AIDS and other manifestations of HIV infection. 4th ed. San Diego (CA): Elsevier Academic Press, 2004: 914–30

    Google Scholar 

  33. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, October 10, 2006 [online]. Available from URL: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Accessed 2006 Oct 16]

  34. Gourevitch MN, Friedland GH. Interactions between metha-done and medications used to treat HIV infection: a review. Mt Sinai J Med 2000; 67: 429–36

    PubMed  CAS  Google Scholar 

  35. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13: 957–62

    Article  PubMed  CAS  Google Scholar 

  36. Abbott Laboratories. Kaletra® (lopinavir/ritonavir) tablets and oral solution. Prescribing information [online]. Abbott Laboratories, North Chicago (IL). Available from URL: http://www.rxabbott.com/pdf/kaletratabpi.pdf [Accessed 2006 Jun 15]

  37. Oldfield V, Plosker GL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2006; 66: 1275–99

    Article  PubMed  CAS  Google Scholar 

  38. Adams C, Balkin A. Proton pump inhibitors (PPIs), antacids and histamine antagonists: what do HIV patients taking PIs know and do [poster no. 4.3/8]? 10th European AIDS Conference; 2005 Nov 17–20; Dublin

  39. Klein CE, Chiu Y-L, Cai Y, et al. Lack of effect of acid reducing agents on the pharmacokinetics (PK) of lopinavir/ritonovir (LPV/r) tablet formulation [poster no. L-1003]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)

  40. Winston A, Boffito M. The management of HIV-1 protease inhibitor pharmacokinetic interactions. J Antimicrob Chemother 2005; 56: 1–5

    Article  PubMed  CAS  Google Scholar 

  41. la Porte C, Cameron DW, Sabo JP, et al. The effect of omeprazole, food and formulation on the pharmacokinetics of tipranavir coadministered with ritonavir [abstract no. 59]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007 Apr 16–18; Budapest

  42. Agarwala S, Eley TVC, Child M, et al. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects [abstract no. 11]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec (QC)

  43. Highleyman L. Drug interactions and anti-HIV therapy. BETA 2005; 17: 20–9

    PubMed  Google Scholar 

  44. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998; 46: 111–6

    Article  PubMed  CAS  Google Scholar 

  45. Chersich MF, Urban MF, Venter FW, et al. Efavirenz use during pregnancy and for women of child-bearing potential [online]. Available from URL: http://www.aidsrestherapy.com/content/3/1/11 [Accessed 2007 Aug 22]

  46. Goicoechea M, Best B. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin Pharmacother 2007; 8: 371–82

    Article  PubMed  CAS  Google Scholar 

  47. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–310

    Article  PubMed  CAS  Google Scholar 

  48. Portsmouth SD, Osorio J, McCormick K, et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005; 6: 185–90

    Article  PubMed  CAS  Google Scholar 

  49. Moyle G. The Assessing Patients’ Preferred Treatments (APPT-1) study. Int J STD AIDS 2003; 14 Suppl. 1: S34–6

    Article  Google Scholar 

  50. Rode R, Vrijens B, Niemi K, et al. Differenes in treatment compliance between lopinavir/ritonovir (LPV/r) given once (QD) versus twice (BID) daily do not affect virological or immunological [poster no. H-522]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16–19; Washington, DC

  51. Vrouenraets SM, Wit FW, van Tongeren J, et al. Efavirenz: a review. Expert Opin Pharmacother 2007; 8: 851–71

    Article  PubMed  CAS  Google Scholar 

  52. Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir, 48-week results from AI124-089 [abstract no. 107LB]. 13th Conference on Retro-viruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)

  53. Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998; 42: 332–8

    PubMed  CAS  Google Scholar 

  54. Electronic Medicines Compendium. Videx product information [online]. Available from URL: http://www.emc.medicines.org.uk/ [Accessed 2006 Nov 27]

  55. Electronic Medicines Compendium. Invirase product information [online]. Available from URL: http://www.emc.medicines.org.uk/ [Accessed 2006 Nov 27]

  56. Breitenbach J. Melt extrusion brings new benefits to HIV therapy. Am J Drug Deliv 2006; 4: 61–4

    Article  CAS  Google Scholar 

  57. Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44: 401–10

    Article  PubMed  CAS  Google Scholar 

  58. Wagner GJ, Ryan GW. Relationship between routinization of daily behaviors and medication adherence in HIV-positive drug users. AIDS Patient Care STDS 2004; 18: 385–93

    Article  PubMed  Google Scholar 

  59. Catz SL, Kelly JA, Bogart LM, et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000; 19: 124–33

    Article  PubMed  CAS  Google Scholar 

  60. Johnson MO, Charlebois E, Morin SF, et al. Perceived adverse effects of antiretroviral therapy. J Pain Symptom Manage 2005; 29: 193–205

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The author would like to thank Porterhouse Medical Ltd for assistance in developing this article. Financial support for this project was provided by Abbott Laboratories. Prof. Fletcher has participated in ad hoc advisory boards for Abbott, Bristol Myers Squibb, GlaxoSmithKline and Tibotec, Inc., and has received honoraria for participation.

Author information

Authors and Affiliations

  1. Clinical Pharmacy and Infectious Diseases, University of Colorado Health Sciences Center, 4200 East 9th Avenue, C-238, Denver, Colorado, 80262, USA

    Courtney V. Fletcher

Authors
  1. Courtney V. Fletcher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Courtney V. Fletcher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fletcher, C.V. Translating Efficacy into Effectiveness in Antiretroviral Therapy. Drugs 67, 1969–1979 (2007). https://doi.org/10.2165/00003495-200767140-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767140-00001

Keywords

Search

Navigation